Bio-Techne (TECH) Land & Improvements (2010 - 2016)
Bio-Techne (TECH) posted quarterly Land & Improvements of $6.3 million for Q2 2016, down 14.93% year-over-year from $7.4 million in Q3 2015, and down 14.93% quarter-over-quarter from $7.4 million in Q2 2015.
Bio-Techne (TECH) Land & Improvements (2010 - 2016) Analysis & Trends
Bio-Techne's Land & Improvements history runs 7 years deep, the most recent figure standing at $6.3 million for Q2 2016.
- In Q2 2016, Land & Improvements fell 14.93% year-over-year to $6.3 million; the TTM figure through Jun 2016 stood at $6.3 million (down 14.93% YoY), while the FY2016 annual figure was $6.3 million, down 14.93% from the prior year.
- Land & Improvements for Q2 2016 stood at $6.3 million, down from $7.4 million in the prior quarter.
- The five-year high for Land & Improvements was $7.5 million in Q4 2012, with the low at $6.3 million in Q2 2016.
- The 5-year median for Land & Improvements is $7.4 million (2013), against an average of $7.4 million.
- The sharpest annual moves came in 2012 and 2016: Land & Improvements grew 0.67% in 2012, then declined 14.93% in 2016.
- Bio-Techne's Land & Improvements stood at $7.5 million in 2012, then fell by 1.09% to $7.4 million in 2013, then slipped by 0.32% to $7.4 million in 2014, then decreased by 0.47% to $7.4 million in 2015, then slipped by 14.93% to $6.3 million in 2016.
- Business Quant data shows TECH's Land & Improvements at $6.3 million in Q2 2016, $7.4 million in Q2 2015, and $7.4 million in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 6.27 Mn |
| Jun 30, 2015 | 7.37 Mn |
| Sep 30, 2014 | 7.41 Mn |
| Jun 30, 2014 | 7.47 Mn |
| Mar 31, 2014 | 7.44 Mn |
| Dec 31, 2013 | 7.43 Mn |
| Sep 30, 2013 | 7.51 Mn |
| Jun 30, 2013 | 7.44 Mn |
| Mar 31, 2013 | 7.44 Mn |
| Dec 31, 2012 | 7.51 Mn |
| Sep 30, 2012 | 7.51 Mn |
| Jun 30, 2012 | 7.47 Mn |
| Mar 31, 2012 | 7.49 Mn |
| Dec 31, 2011 | 7.46 Mn |
| Sep 30, 2011 | 7.46 Mn |
| Jun 30, 2011 | 7.50 Mn |
| Jun 30, 2010 | 7.42 Mn |